Swiss speciality pharmaceuticals firm Santhera has announced that it will list up to 983,859 shares on the Swiss Stock Exchange. Assuming that the IPO is successful this will raise approximately SFr 83.6m-SFr 98.4m, excluding an over-allotment option. This will put the company's free-float proportion at 33.3%. The listing is due to take place on 3 November.
Deal includes three manufacturing facilities located in Spain, which employ around 140 staff
GP acquired the care home group from Swiss Prime Site and will be the company's sole shareholder
Iris, Idinvest and historical backers invest in the manager of the eponymous social media app
GP uses its Mérieux Participations 3 fund, which held a first close on €200m in 2018